Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28407960 | 0.89 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL27453998 | 0.81 | HTR2A (0.35) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL28290766 | 0.81 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL1796846 | 0.80 | ALDH1A1 (0.44) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL27299166 | 0.80 | L3MBTL1 (0.38) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL11412833 | 0.80 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1PKMLMNAMAPT | |
| SCHEMBL27927715 | 0.79 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL11416392 | 0.79 | MAPT (0.37) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL2977912 | 0.77 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL28016917 | 0.77 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1PKMHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777196-B | Method for synthesizing Ai Fulin amide isomer derivative | 常州大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12545649-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117777196-A | Method for synthesizing Ai Fulin amide isomer derivative | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20230022304-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| WO-2008005956-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005956-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545649-B2 | WDR5-MYC inhibitors | MYC, MYCBP, WDR1 | ALDH1A1 4135/4885L3MBTL1 517/4885PKM 4769/4885 |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | ALDH1A1 3049/4885L3MBTL1 4590/4885PKM 405/4885 |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | ALDH1A1 1040/4885L3MBTL1 3722/4885PKM 1616/4885 |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | ALDH1A1 651/4885L3MBTL1 2917/4885PKM 1968/4885 |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | ALDH1A1 1040/4885L3MBTL1 3722/4885PKM 1616/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885L3MBTL1 1142/4885PKM 4363/4885 |
| US-20230022304-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | ALDH1A1 3982/4885L3MBTL1 702/4885PKM 3991/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | ALDH1A1 4493/4885L3MBTL1 1142/4885PKM 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.